drugset
drugset / Trial / NCT06533059

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059 ↗

Phase 1 Active not recruiting 110 enrolled Alterome Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Timeline

Start
2024-08-22
Primary completion
2026-12-29
Completion
2027-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ALTA2618 Unknown — Oral

Indications

breast cancer endometrial cancer metastatic malignant neoplasm